Freeman Jonathan E 4

What Happened

• Jonathan E. Freeman, a director of Phio Pharmaceuticals Corp. (PHIO), was granted 16,600 restricted stock units (RSUs) on 2026-02-05. The reported acquisition price is $0.00, so the grant has no immediate cash cost reported. This transaction is an award/compensation grant (Form 4 code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-05; filing date: 2026-02-06 (filed within typical Form 4 timeliness window).
• Quantity and price: 16,600 RSUs @ $0.00; reported total value on grant = $0 based on price reported.
• Shares owned after transaction: Not specified in the provided filing summary.
• Footnotes: F1 — these RSUs represent shares that will vest on the first annual anniversary of the grant. F2 — filing aggregates shares that include common stock underlying unvested RSUs. F3 — reported counts have been adjusted for prior reverse stock splits.
• Transaction code: A (award/grant).

Context

• RSUs are a form of compensation that convert into shares if vesting conditions are met; they do not represent an immediate cash investment or sale. Because this is a compensation grant to a director, it’s routine corporate compensation rather than a direct bullish or bearish trading signal.